The latent period of recipient mice with MLL-AF9-transformed Mbd2−/− cells was significantly longer than that of the WT mice, indicating that MBD2 deficiency delayed leukemia onset (Fig. 1G, H). This evidence concerns the gene MLLT3 and leukemia.